New Products
Hexaxim (DTPa-hepB-IPV-Hib vaccine) combines diphtheria toxoid, tetanus toxoid, acellular pertussis (toxoid and filamentous haemagglutinin), recombinant hepatitis B surface antigen, inactivated poliomyelitis virus and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. Hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. Hexaxim should not be administered to anyone with a history of severe allergic reaction to any pertussis vaccine; encephalopathy of unknown aetiology within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines); progressive neurological disorder, uncontrolled epilepsy or progressive encephalopathy until the treatment regimen has been established, the condition has stabilised and the benefit clearly outweighs the risk. Generally vaccination must be postponed in cases of moderate or severe febrile and/or acute disease. Hexaxim is supplied in a 0.5 mL single dose prefilled syringe (without attached needle and one or two separate needles) in a pack size of 1 or 10.
NovoThirteen (catridecacog (rys)) is a recombinant human coagulation factor XIII A-subunit. Factor XIII is the terminal enzyme in the blood coagulation cascade. When activated by thrombin at the site of vessel wall injury, factor XIII plays an important role in the maintenance of haemostasis through cross-linking of fibrin and other proteins in the fibrin clot. NovoThirteen is indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. NovoThirteen lyophilised powder for injection is available in a single use vial containing 2500 IU in a pack of 1.
Rexulti (brexpiprazole) is a novel atypical antipsychotic agent with pharmacological activity as a serotonin-dopamine activity modulator. Brexpiprazole combines partial agonist activity at serotonergic 5HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5HT2A receptors. Rexulti is indicated for the treatment of schizophrenia in adults. Rexulti is available as 1 mg, 2 mg, 3 mg and 4 mg tablets in pack sizes of 30.
Somavert (pegvisomant (rbe)) is an analogue of human growth hormone that has been genetically modified to be a growth hormone receptor antagonist. Somavert is indicated for the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. The treatment goal is to normalise insulin-like growth factor-I levels. Somavert is supplied as lyophilised powder for injection in single dose vials containing 10 mg (packs of 30), 15 mg (packs of 30) and 20 mg (packs of 1 and 30).
Tecentriq (atezolizumab (rch)) is a humanised monoclonal antibody that directly binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 pathway mediated inhibition of the immune response, including reactivating the anti-tumour immune response. Tecentriq is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy. In patients with tumour EGFR or ALK genomic aberrations, Tecentriq should be used after progression on or after targeted therapy. Tecentriq concentrated solution for intravenous infusion is available in a single use vial containing 1200 mg per 20 mL in a pack of 1.